IP Library › Granted Patent US 12,735,670
Granted Patent B2
US 12,735,670 · App. 18/158,213 · Granted Sep 15, 2026

Support structures for automated cell engineering systems

Inventors: Scott Parsons (Kingston, CA); Mike Loveless (Kingston, CA); Kevin Meric (Kingston, CA); Wes Chamberlin (Kingston, CA); Robert Magyar (Kingston, CA); Michael Nuttall (Kingston, CA); Ammar Al-Dojaily (Kingston, CA); Rade Gadzic (Kingston, CA)
Assignee: OCTANE BIOTECH INC.
C12M41/48C12M23/44C12M23/48C12M29/08C12M41/12C12M41/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,670
App. No.
18/158,213
Granted
Sep 15, 2026
Kind
B2
Abstract

The present technology is generally related to storage structures for cell engineering systems. The storage structures allow for multiple automated cell engineering systems to be held via a single structure, and presented to a user when desired or needed for direct access to the cell engineering system, and then returned to a storage or working position. Many storage structures can be arranged together in a clinical or hospital setting, or other cell therapy engineering manufacturing environment.

Claims (14)

1 . An automated selection and support system comprising:

a plurality of automated biologic processing units, each of the plurality of automated biologic processing units being translatable between at least a first position for storage and maintaining the plurality of automated biologic processing units, and a second position for presenting at least one or more of the plurality of automated biologic processing units;

a movable support structure for transitioning each of the plurality of automated biologic processing units between the first position and the second position;

an electrical system including a power supply and an interface device, both the power supply and the interface device being operatively connected to each of the plurality of automated biologic processing units and the movable support structure; and

a gas supply system including a gas line fluidly coupled to each of the plurality of automated biologic processing units;

wherein the electrical system and the gas supply system are both operatively connected to each of the automated biologic processing units via a single axis of connection comprising a connection conduit, and the connection conduit is configured to travel with each automated biologic processing unit between the first position and the second position.

2 . The system of claim 1 , wherein the plurality of automated biologic processing units are translatable to a plurality of positions between the first position for storage and maintaining, and the second position for presenting the at least one or more of the plurality of automated biologic processing units.

3 . The system of claim 1 , wherein the plurality of automated biologic processing units are autonomous such that each of the plurality of automated biologic processing units individually regulate and adjust various functions and controls to maintain a desired environment within each of the plurality of automated biologic processing units in real time.

4 . The system of claim 3 , wherein the various functions and controls include heating control, cooling control, gas control, tilt control, fan control, data memory, pump control, valve actuator control, seal control, door control, magnetic separation control, and/or elapsed time indication.

5 . The system of claim 1 , wherein translating at least one of the plurality of automated biologic processing units does not impact an activating, transducing, expanding, concentrating, and/or harvesting steps of cell cultures within the remaining plurality of automated biologic processing units.

6 . The system of claim 1 , further comprising a heat management system configured to circulate a fluid to heat or cool each of the plurality of automated biologic processing units.

7 . The system of claim 1 wherein the interface device is a separate unit allowing for remote access/connection.

8 . The system of claim 1 , wherein the interface device is physically coupled to the system.

9 . The system of claim 1 , wherein the electrical system operably controls the movable support structure such that each of the plurality of automated biologic processing units are maintained in a level position while transitioning between the first position and the second position.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2023
From: PARSONS, SCOTT; LOVELESS, MIKE; MERIC, KEVIN; AL-DOJAILY, AMMAR; GADZIC, RADE; CHAMBERLIN, WES; MAGYAR, BOB
To: STARFISH PRODUCT ENGINEERING INC.
Reel/Frame 064325/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2023
From: NUTTALL, MICHAEL
To: OCTANE BIOTECH, INC.
Reel/Frame 064325/0747 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2023
From: STARFISH PRODUCT ENGINEERING INC.
To: OCTANE BIOTECH, INC.
Reel/Frame 064326/0056 →
Continuity (2)
Provisional Application 63302366 · Jan 24, 2022
Related Publication 20230235268A1 · Jul 27, 2023
References Cited (78)
US 4939151A · Bacehowski et al. · 1990 [cited by applicant]
US 5424209A · Kearney · 1995 [cited by applicant]
US 5478479A · Herrig · 1995 [cited by applicant]
US 5985653A · Armstong et al. · 1999 [cited by applicant]
US 5989913A · Anderson et al. · 1999 [cited by applicant]
US 5994129A · Armstrong et al. · 1999 [cited by applicant]
US 6048721A · Armstrong et al. · 2000 [cited by applicant]
US 6048722A · Farb et al. · 2000 [cited by applicant]
US 6096532A · Armstrong et al. · 2000 [cited by applicant]
US 6123655A · Fell · 2000 [cited by applicant]
US 6197575B1 · Griffith et al. · 2001 [cited by applicant]
US 6214574B1 · Kopf · 2001 [cited by applicant]
US 6228635B1 · Armstrong et al. · 2001 [cited by applicant]
US 6238908B1 · Armstrong et al. · 2001 [cited by applicant]
US 6297046B1 · Smith et al. · 2001 [cited by applicant]
US 6402941B1 · Lucido et al. · 2002 [cited by applicant]
US 7906323B2 · Cannon et al. · 2011 [cited by applicant]
US 9629877B2 · Cooper et al. · 2017 [cited by applicant]
US 10131876B2 · Kaiser et al. · 2018 [cited by applicant]
US 10253316B2 · Masquelier et al. · 2019 [cited by applicant]
US 10273300B2 · Bedoya et al. · 2019 [cited by applicant]
US 20010021529A1 · Takagi · 2001 [cited by applicant]
US 20020025547A1 · Rao · 2002 [cited by applicant]
US 20020179525A1 · Shaffer et al. · 2002 [cited by applicant]
US 20080160591A1 · Willson et al. · 2008 [cited by applicant]
US 20100316446A1 · Runyon · 2010 [cited by examiner]
US 20150140653A1 · Jones et al. · 2015 [cited by applicant]
US 20150344844A1 · Better et al. · 2015 [cited by applicant]
US 20160122782A1 · Crisman et al. · 2016 [cited by applicant]
US 20170037369A1 · Ramsborg et al. · 2017 [cited by applicant]
US 20170051252A1 · Morgan et al. · 2017 [cited by applicant]
US 20170341873A1 · Vivet et al. · 2017 [cited by applicant]
US 20180104697A1 · Butler · 2018 [cited by examiner]
US 20190017009A1 · Yu · 2019 [cited by applicant]
US 20190211294A1 · Karnieli · 2019 [cited by applicant]
US 20200131460A1 · Higuchi et al. · 2020 [cited by applicant]
US 20200200781A1 · Smith et al. · 2020 [cited by applicant]
US 20210095239A1 · Recker · 2021 [cited by examiner]
US 20210246406A1 · Roberts · 2021 [cited by examiner]
KR 20000023786U · 2001 [cited by applicant]
WO 9712960A2 · 1997 [cited by applicant]
WO 9947922A2 · 1999 [cited by applicant]
WO 0100783A2 · 2001 [cited by applicant]
WO 2015162211A1 · 2015 [cited by applicant]
WO 2016069993A1 · 2016 [cited by applicant]
WO 2016118780A1 · 2016 [cited by applicant]
WO 2016168275A1 · 2016 [cited by applicant]
WO 2017068425A1 · 2017 [cited by applicant]
WO 2018015561A1 · 2018 [cited by applicant]
WO 2018136566A1 · 2018 [cited by applicant]
Aitken-Christie et al., Automation in Plant tissue culture—general introduction and overview, in Automation and Environmental Control in Plant Tissue Culture 757 (J. Aitken-Christie, T. Kozai & M. Lila Smith eds., 1995). [cited by applicant]
Apel et al., Integrated Clinical Scale Manufacturing System for Cellular Products Derived by Magnetic Cell Separation, Centrifugation and Cell Culture, Chemie Ingenieur Technik (2013). [cited by applicant]
Armstrong et al., Clinical Systems for the Production of Cells and Tissues for Human Therapy, in Novel Therapeutics From Modern Biotechnology 221 (D.L. Oxender et al. eds., 1999). [cited by applicant]
Blaeschke et al., Induction of a Central Memory and Stem Cell Memory Phenotype in Functionally Active CD4+ and CD8+ CAR T Cells Produced in an Automated Good Manufacturing Practice System for the Treatment of CD19+ Acut… [cited by applicant]
Bohnenkamp et al., Bioprocess development for the cultivation of human T-lymphocytes in a clinical scale, Cytotechnology (2002). [cited by applicant]
Bousso, T-cell activation by dendritic cells in the lymph node: lessons from the movies, 8 Nature Reviews Immunology 675 (2008) (“Bousso 2008”). [cited by applicant]
Kaiser et al., Towards a Commercial Process for the Manufacture of Genetically Modified T Cells for Therapy, 22 Cancer Gene Therapy 72-78 (2015). [cited by applicant]
Kempner et al., A Review of Cell Culture Automation, 7 Journal of the Association for Laboratory Automation 56 (2002) (“Kempner 2002”). [cited by applicant]
Koller et al., Clinical-scale human umbilical cord blood cell expansion in a novel automated perfusion culture system, Bone Marrow Transplantation (1998) (“Koller 1998”). [cited by applicant]
Koller et al., Large-Scale Expansion of Human Stem and Progenitor Cells from Bone Marrow Mononuclear Cells in Continuous Perfusion Cultures, Blood (1993) (“Koller 1993A”). [cited by applicant]
Koller et al., Tissue Engineering: Reconstitution of Human Hematopoiesis Ex Vivo, Biotechnology and Bioengineering (1993) (“Koller 1993B”). [cited by applicant]
Kostov et al., Low-Cost Microbioreactor for High-Throughput Bioprocessing, 72 Biotechnology and Bioengineering, Feb. 5, 2001 (“Kostov 2001”). [cited by applicant]
Krug et al., A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor, Cancer Immunol Immunotherapy (2014) (“Krug 2014”). [cited by applicant]
Levine et al., Global Manufacturing of CAR T Cell Therapy, 4 Molecular Therapy: Methods & Clinical Development 92 (2017). [cited by applicant]
Lock et al., Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use, 28 Human Gene Therapy 10 (2017), (“Lock 2017”). [cited by applicant]
Lu et al., A Rapid Cell Expansion Process for Production of Engineered Autologous CART Cell Therapies, 27 Human Gene Therapy 6 (2016). [cited by applicant]
Mock et al., Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy, Cytotherapy (2016). [cited by applicant]
Morse, Technology evaluation: Stem-cell therapy, Aastrom Biosciences Inc., Current Opinion in Molecule Therapeutics (1999) (“Morse 1999”). [cited by applicant]
Oh et al., Frequent Harvesting from Perfused Bone Marrow Cultures Results in Increased Overall Cell and Progenitor Expansion, Biotechnology and Bioengineering (1994). [cited by applicant]
Priesner et al., Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L+ T Cells for Manufacturing of Gene Therapy Medicinal Products, 27 Human Gene Therapy 10, 860-869 (2016). [cited by applicant]
Rosazza et al., Gene Electrotransfer: A Mechanistic Perspective, Current Gene Therapy (2016) (“Rosazza 2016”). [cited by applicant]
Shi et al., “Performance of Mammalian Cell Culture Bioreactor with a New Impeller Design” Biotechnology and Bioengineering, vol. 40, pp. 260-270 (1992). [cited by applicant]
Stiff et al., Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer, Blood (2000) (“Stiff 2000”). [cited by applicant]
Wang et al., Clinical Manufacturing of CAR T Cells: Foundation of a Promising Therapy, 3 Molecular Therapy—Oncolytics 1 (2016). [cited by applicant]
Wang et al., Manufacture of Tumor- and Virus-specific T Lymphocytes for Adoptive Cell Therapies, 22 Cancer Gene Therapy 2 (2015). [cited by applicant]
Zhang et al., Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system, Drug Design, Development and Therapy (2018) (“Zhang 2018”). [cited by applicant]
Zhu et al., Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center, Cytotherapy (2018). [cited by applicant]
Basic and Clinical Immunology: Antigen Presentation, T Cell Activation and Deactivation, Clevelandcliniccme, found at https://www.youtube.com/watch?v=EfYpkA4AmFo (2017), last visited Dec. 6, 2020 (“Cleveland Clinic vide… [cited by applicant]